🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Ganzhou Hemay Pharmaceutical clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Ganzhou Hemay Pharmaceutical as lead sponsor. Synced 26 Sep 2026
7Current trials
4Recruiting now
3Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Ganzhou Hemay Pharmaceutical is the lead sponsor of 7 current clinical trials in our China register. 4 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Mufemilast, Hemay181 and Roflumilast. The most-studied condition is Advanced Solid Tumors.

ClinicalTrials.gov trials by status

  • Recruiting457%
  • Not yet open229%
  • Active, closed114%

Trials by phase

  • Phase 1343%
  • Phase 2229%
  • Phase 3229%
01

Clinical trials sponsored by Ganzhou Hemay Pharmaceutical

7 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181
NCT07446816 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Drug: Hemay181
Phase 1 Recruiting 2025-12 China
To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage
NCT06376474 · ClinicalTrials.gov ↗ · Psoriasis
Phase 1 Recruiting 2024-04 China
A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
NCT06145893 · ClinicalTrials.gov ↗ · Behçet's Disease
Phase 3 Recruiting 2023-11 China
A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors
NCT05749432 · ClinicalTrials.gov ↗ · Solid Tumor
Drug: Hemay181
Phase 1 Recruiting 2023-03 China
A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD
NCT07314242 · ClinicalTrials.gov ↗ · COPD (Chronic Obstructive Pulmonary Disease)
Phase 2 Not yet open 2026-01 China
Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis
NCT07650942 · ClinicalTrials.gov ↗ · Ulcerative Colitis (UC)
Phase 3 Not yet open 2026-06 China
Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis
NCT05486104 · ClinicalTrials.gov ↗ · Moderate to Severe Ulcerative Colitis
Phase 2 Active, closed 2022-11 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Ganzhou Hemay Pharmaceutical trials

3 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Ganzhou Hemay Pharmaceutical trials

7 conditions
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China74

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Advanced Solid Tumors

SponsorTrials
Sichuan Kelun-Biotech Biopharmaceutical9
Jiangsu HengRui Medicine7
Suzhou Suncadia Biopharmaceuticals7
Shanghai Hengrui Pharmaceutical6
Bristol-Myers Squibb5
MediLink Therapeutics (Suzhou)5
Hangzhou Zhongmei Huadong Pharmaceutical5
Hansoh BioMedical R&D Company4
Bayer3
Vividion Therapeutics3

Sponsors with the most current trials registered for this condition.

06

Questions about Ganzhou Hemay Pharmaceutical trials

How many clinical trials does Ganzhou Hemay Pharmaceutical sponsor?

Ganzhou Hemay Pharmaceutical is the lead sponsor of 7 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Ganzhou Hemay Pharmaceutical trials recruiting?

Yes. 4 of its 7 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Ganzhou Hemay Pharmaceutical testing?

Its current trials name 3 drugs and biologicals as interventions. The most frequent are Mufemilast (4), Hemay181 (2) and Roflumilast (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.